Talha Munir

5.7k total citations
81 papers, 754 citations indexed

About

Talha Munir is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Talha Munir has authored 81 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 34 papers in Immunology and 30 papers in Pathology and Forensic Medicine. Recurrent topics in Talha Munir's work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (30 papers) and Complement system in diseases (25 papers). Talha Munir is often cited by papers focused on Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (30 papers) and Complement system in diseases (25 papers). Talha Munir collaborates with scholars based in United Kingdom, United States and Italy. Talha Munir's co-authors include Morag Griffin, Peter Hillmen, Andy C. Rawstron, Adrian Bloor, John G. Gribben, Chris Fegan, Anna Schuh, Andrew R. Pettitt, Kristian Brock and Rebecca Bishop and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Talha Munir

67 papers receiving 742 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Talha Munir United Kingdom	17	524	356	316	215	99	81	754
Stefano Volpetti Italy	12	187 0.4×	220 0.6×	78 0.2×	308 1.4×	38 0.4×	26	538
Judith C. Andersen United States	11	144 0.3×	139 0.4×	83 0.3×	443 2.1×	44 0.4×	17	721
Kenneth Douglas United Kingdom	12	115 0.2×	63 0.2×	462 1.5×	423 2.0×	235 2.4×	23	886
Emma Cacciola Italy	12	211 0.4×	75 0.2×	66 0.2×	214 1.0×	20 0.2×	42	521
Sonja Burgstaller Austria	15	418 0.8×	122 0.3×	83 0.3×	419 1.9×	12 0.1×	49	918
Ronit Gurion Israel	17	216 0.4×	344 1.0×	102 0.3×	237 1.1×	9 0.1×	83	830
C.‐M. Wendtner Germany	11	336 0.6×	317 0.9×	202 0.6×	91 0.4×	5 0.1×	30	662
Zafer Başlar Türkiye	13	182 0.3×	119 0.3×	44 0.1×	307 1.4×	22 0.2×	82	578
Simona Pagliuca France	14	168 0.3×	40 0.1×	176 0.6×	314 1.5×	28 0.3×	69	594
Samo Zver Slovenia	11	144 0.3×	34 0.1×	249 0.8×	207 1.0×	116 1.2×	52	542

Countries citing papers authored by Talha Munir

Since Specialization

Citations

This map shows the geographic impact of Talha Munir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talha Munir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talha Munir more than expected).

Fields of papers citing papers by Talha Munir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Talha Munir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talha Munir. The network helps show where Talha Munir may publish in the future.

Co-authorship network of co-authors of Talha Munir

This figure shows the co-authorship network connecting the top 25 collaborators of Talha Munir. A scholar is included among the top collaborators of Talha Munir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Talha Munir. Talha Munir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rawstron, Andy C., David Cairns, Nichola Webster, et al.. (2025). Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.. Blood. 146(Supplement 1). 794–794.

Griffin, Morag, Shreyans Gandhi, Richard J. Kelly, et al.. (2024). Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial. Haematologica. 110(4). 967–971.

Kelly, Richard, Talha Munir, Petra Muus, et al.. (2023). 52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab. Blood. 142(Supplement 1). 2716–2716. 1 indexed citations

Kelly, Richard, Matthew T. Holt, Jennifer Vidler, et al.. (2023). Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria. Blood. 143(12). 1157–1166. 21 indexed citations

Wang, Michael, Nirav N. Shah, Wojciech Jurczak, et al.. (2023). MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment. Clinical Lymphoma Myeloma & Leukemia. 23. S459–S459. 1 indexed citations

Kater, Arnon P., Carol Moreno, Talha Munir, et al.. (2023). P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL. HemaSphere. 7(S3). e56748d2–e56748d2. 1 indexed citations

Jurczak, Wojciech, Pier Luigi Zinzani, Toby A. Eyre, et al.. (2023). P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT. HemaSphere. 7(S3). e45636b5–e45636b5. 1 indexed citations

Shah, Nirav N., Wojciech Jurczak, Pier Luigi Zinzani, et al.. (2023). Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.. Journal of Clinical Oncology. 41(16_suppl). 7514–7514. 1 indexed citations

Ghia, Paolo, Talha Munir, Jan A. Burger, et al.. (2023). P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS. HemaSphere. 7(S3). e78258de–e78258de. 1 indexed citations

10.

Seymour, John F., John C. Byrd, Paolo Ghia, et al.. (2023). Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 142(8). 687–699. 62 indexed citations

11.

Griffin, Morag, et al.. (2022). Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood. 141(1). 116–120. 9 indexed citations

12.

Munir, Talha, et al.. (2021). To determine the diagnostic accuracy of aspartate aminotransferase to platelet ratio index in detecting significant fibrosis in chronic hepatitis C patients by using histopathology as gold standard.. The Professional Medical Journal. 28(8). 1166–1171.

13.

Munir, Talha. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. 2 indexed citations

14.

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 37(30). 2722–2729. 180 indexed citations

15.

Hillmen, Peter, Talha Munir, Andy C. Rawstron, et al.. (2017). Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood. 130. 428–428. 25 indexed citations

16.

Newton, Darren, Alonso Ricardo, Louise Arnold, et al.. (2017). Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab. Blood. 130. 3484–3484. 3 indexed citations

17.

Griffin, Morag, Talha Munir, Peter Hillmen, et al.. (2017). Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria. Blood. 130. 1175–1175. 1 indexed citations

18.

Richards, Stephen J., Talha Munir, Morag Griffin, et al.. (2017). Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. Blood. 130. 3471–3471. 21 indexed citations

19.

Hill, Anita, Miles A. Nunn, Tadeusz Robak, et al.. (2017). Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial. Blood. 130. 4747–4747. 4 indexed citations

20.

Munir, Talha. (2007). Microscopic observation drug susceptibility assay for the diagnosis of TB. Thorax. 62(10). 847–847. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact